Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of 610 in adults with asthma
CTR20241581Phase 3Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 610 in asthma, sponsored by 3S Guojian Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
610
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20241581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241581.